Fulcrum Therapeutics (NASDAQ:FULC) reported fourth-quarter and full-year 2025 results highlighted by positive 12-week data for its lead candidate, pociredir.
The Phase 1b PIONEER trial, evaluating the small molecule in patients with sickle cell disease (SCD), met its primary objectives with a "rapid and robust" induction of fetal hemoglobin (HbF).
In the 20 mg dose cohort, patients saw a mean absolute increase in HbF of 12.2%, rising from a baseline of 7.1% to 19.3% by the end of the 12-week period.
Seven of the 12 evaluable patients achieved absolute HbF levels of at least 20%, a threshold clinicians frequently associate with improved outcomes and a reduction in vaso-occlusive crises (VOCs).
Fulcrum also reported improvements across multiple secondary markers, including total hemoglobin levels and reduced signs of hemolysis and anemia.
The company ended the fiscal year with $352.3 million in cash, cash equivalents, and marketable securities.
This balance sheet was significantly bolstered by a $164.2 million public offering in December 2025.
Management reiterated that current liquidity is sufficient to fund operations into 2029, covering the critical window for its upcoming registration-enabling trial.
As part of its portfolio high-grading, Fulcrum announced it would discontinue its bone marrow failure syndromes program to focus resources on the "benign hematology" franchise.
The company is currently preparing for an end-of-phase meeting with the FDA to finalize the design for its next study, which is expected to initiate in the second half of 2026.